Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.
Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center.
Biosplice's leading drug is targeted to treat knee osteoarthritis with the goal of alleviating pain and the aim of restoring tissue balance and protecting from cartilage loss. Biosplice's clinical pipeline also focuses on oncology, with additional early-stage programs in neurology and other areas of significant unmet medical needs.
Location: United States, California, San Diego
Total raised: $120M
Investors 2
| Date | Name | Website |
| - | aMoon Fund | amoon.fund... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.04.2021 | - | $120M | aMoon Fund |
Mentions in press and media 2
| Date | Title | Description | Source |
| 08.03.2024 | Biosplice Therapeutics Announces Department of Defense (DoD)... | - | globenewsw... |
| 08.03.2023 | Finding the Fountain of Youth: Meet the Startups Pioneering ... | If technology allowed humanity to live forever in the future, would you take the ticket? We asked ou... | therecursi... |